上海中信国健药业股份有限公司
上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。
作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列。

Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.

请符合条件的应聘者将中英文简历、学历证书、身份证复印件寄至以下地址：上海市张江高科技园区李冰路399号上海中信国健药业股份有限公司 人力资源部 钟先生  收（邮编：201203） 或 发送E-mail至hr@cpgj-pharm.com （请在信封上或邮件题目上注明应聘职位）。
请勿来电来访，恕不接待。